ASIATODAY

BIZ&TECH

Immunomic Therapeutics doses first patient in phase 1 trial for allergy vaccine

HLB announced on July 3 that its US subsidiary, Immunomic Therapeutics, has completed the dosing of the first patient in the Phase 1 clinical trial for its Japanese cedar pollinosis vaccine candidate, ITI-9001. The patient has reportedly shown no specific adverse events or safety issues following the administration. This first dosing was achieved less than..

Ethereum and Solana rebound 7% in a day amid market crash—here's why
Ethereum and Solana, major altcoins, are drawing attention as they surged more than 7% in a single day. While the overall crypto market continues to show w..

MOTIE to launch ‘Manufacturing Data Vault'

previous block

11 12 13 14 15 16 17 18 19 20

next block

Most Read

1

Heung-min Son says "I'm sorry," but fans..

2

Chinese tourists' resumption of travel to Japan fa..

3

Iran’s IRGC attacks cargo ship in Strait of Hormuz..

4

Right-wing Fujimori wins Peru's presidential elect..

5

Myanmar junta eyes ASEAN return amid regional embr..

6

U.S. Defense Secretary announces review of America..

7

Japan invests 2 trillion yen in India to shift chi..

PEOPLE

"Hallyu ban to be removed quickly": Hopes of thaw in Seoul-Beijing ties: · "Efforts will be made to remove Hallyu ban quickly"; · SK Group Chairman heads to Japan to soften "WD risk"

PHOTO

Jang Won-young shines as BVLGARI’s holiday muse

S.KOREA

POLITICS

SOCIAL AFFAIRS

WORLD

CHINA

INDIA

OTHERS

ECONOMY

BIZ&TECH

CULTURE

PEOPLE

PHOTO

Address : In-Young Bldg., 34, Uisadang-daero 1-gil, Yeongdeungpo-gu, Seoul

Copyright by ASIATODAY CO., LTD. All rights resereved